Solid Lipid Nanoparticles Formulations Research Articles

Examination of the effects of vitexin and vitexin-loaded solid lipid nanoparticles on neuropathic pain and possible mechanisms of action

This research aims to investigate the possible antiallodynic and antihyperalgesic effects of pure vitexin and vitexin-loaded solid lipid nanoparticles (SLN) on neuropathic pain and the pathways mediating these effects. Chronic constriction nerve injury was induced in female rats, and the effects of vitexin at the doses of 5, 10, 20, 40 mg/kg were evaluated. Ketanserin, ondansetron, WAY-100635, yohimbine and bicuculin, which are antagonists of receptors on pain pathways. were used to examine the mechanisms of the effects of vitexin. Pure vitexin exhibited antiallodynic activity at all administered doses, whereas antihyperalgesic activity was not observed at 5 mg/kg vitexin dose. SLN formulation was prepared with 5 mg/kg vitexin, the lowest dose. Vitexin-loaded formulation significantly increased antiallodynic and antihyperalgesic effects. Ondansetron, WAY-100635, yohimbine, and bicuculine antagonized the antiallodynic and antihyperalgesic effects of vitexin. So, it was concluded that serotonin (5-hydroxtryptamine, 5-HT) receptor subtypes 5-HT3 and 5-HT1A, alpha-2 adrenergic, and γ-Aminobutyric acid type A (GABA-A) receptors are involved in the antiallodynic and antihyperalgesic activity of vitexin. In conclusion, vitexin and vitexin-loaded formulation have the potential for clinical use in neuropathic pain management, and different pain pathways contributed to this effect. And also, it is thought that vitexin-loaded SLN formulation is more effective than pure vitexin, which will provide an advantage in treatment.

Dopamine- and Grape-Seed-Extract-Loaded Solid Lipid Nanoparticles: Interaction Studies between Particles and Differentiated SH-SY5Y Neuronal Cell Model of Parkinson's Disease.

Parkinson's disease (PD) is a prevalent neurodegenerative disorder, primarily associated with dopaminergic neuron depletion in the Substantia Nigra. Current treatment focuses on compensating for dopamine (DA) deficiency, but the blood-brain barrier (BBB) poses challenges for effective drug delivery. Using differentiated SH-SY5Y cells, we investigated the co-administration of DA and the antioxidant Grape Seed Extract (GSE) to study the cytobiocompability, the cytoprotection against the neurotoxin Rotenone, and their antioxidant effects. For this purpose, two solid lipid nanoparticle (SLN) formulations, DA-co-GSE-SLNs and GSE-ads-DA-SLNs, were synthesized. Such SLNs showed mean particle sizes in the range of 187-297 nm, zeta potential values in the range of -4.1--9.7 mV, and DA association efficiencies ranging from 35 to 82%, according to the formulation examined. The results showed that DA/GSE-SLNs did not alter cell viability and had a cytoprotective effect against Rotenone-induced toxicity and oxidative stress. In addition, this study also focused on the evaluation of Alpha-synuclein (aS) levels; SLNs showed the potential to modulate the Rotenone-mediated increase in aS levels. In conclusion, our study investigated the potential of SLNs as a delivery system for addressing PD, also representing a promising approach for enhanced delivery of pharmaceutical and antioxidant molecules across the BBB.

Antidiabetic Drug-loaded Solid Lipid Nanoparticle and Its Importance in Drug Delivery

The global health challenge of diabetes mellitus continues to escalate, affecting millions of people worldwide. Managing this chronic condition necessitates lifelong treatment to control hyperglycemia and prevent complications. The delivery of antidiabetic medications can be improved by solid lipid nanoparticles (SLNs). This review provides an overview of current research on antidiabetic-loaded SLNs, summarizing their efficacy, safety, and challenges. Various antidiabetic agents, including insulin, metformin, sulfonylureas, and GLP-1 agonists, have been successfully encapsulated into SLNs, offering improved pharmacokinetic profiles and therapeutic outcomes. Despite their potential, optimization of SLN formulations, scale-up challenges, and translation to clinical practice remain areas requiring further investigation. With ongoing advancements in nanotechnology and drug delivery, antidiabetic-loaded SLNs hold promise for revolutionizing diabetes therapy and improving patient care

Anticancer and Chemosensitizing Effects of Menadione-Containing Peptide-Targeted Solid Lipid Nanoparticles

Vitamin K derivatives such as menadione (MD) have been recognized as promising redox-modulating and chemosensitizing agents for anticancer therapy, however, their cellular activities in peptide-targeted nanocarriers have not been elucidated to date. This study provides the guidelines for developing MD-loaded solid lipid nanoparticles (SLN) modified with extracellular matrix (ECM)-derived peptides. Relationships between RGD peptide concentration and changes in DLS characteristics as well as accumulation of SLN in cancer cells were revealed to adjust the peptide-lipid ratio. SLN system maintained adequate nanoparticle concentration and low dispersity after introduction of MD and MD/RGD, whereas formulated MD was protected from immediate conjugation with reduced glutathione (GSH). RGD-modified MD-containing SLN showed enhanced prooxidant, GSH-depleting and cytotoxic activities toward PC-3 prostate cancer cells attributed to improved cellular pharmacokinetics of the targeted formulation. Furthermore, this formulation effectively sensitized PC-3 cells and OVCAR-4 ovarian cancer cells to free doxorubicin and cisplatin so that cell growth was inhibited by MD–drug composition at nontoxic concentrations of the ingredients. These results provide an important background for further improving chemotherapeutic methods based on combination of conventional cytostatics with peptide-targeted SLN formulations of MD.

Development of cationic solid lipid nanoparticles incorporating cholesteryl-9-carboxynonanoate (9CCN) for delivery of antagomiRs to macrophages

Lipid-based nanoparticles are a useful tool for nucleic acids delivery and have been regarded as a promising approach for diverse diseases. However, off-targets effects are a matter of concern and some strategies to improve selectivity of solid lipid nanoparticles (SLNs) were reported. The goal of this study was to test formulations of SLNs incorporating lipid cholesteryl-9-carboxynonanoate (9CCN) as “eat-me” signal to target antagomiR oligonucleotides to macrophages. We formulate four SLNs, and those with a mean diameter of 200 nm and a Z-potential values between 25 and 40 mV, which allowed the antagomiR binding, were selected for in vitro studies. Cell viability, transfection efficiency and cellular uptake assays were performed within in vitro macrophages using flow cytometry and confocal imaging and the SLNs incorporating 25 mg of 9CCN proved to be the best formulation. Subsequently, we used a labeled antagomiR to study tissue distribution in in-vivo ApoE-/- model of atherosclerosis. Using the ApoE-/- model we demonstrated that SLNs with phagocytic signal 9-CCN target macrophages and release the antagomiR cargo in a selective way.

A Comprehensive Review on Solid Lipid Nanoparticles

This review provides a comprehensive analysis of solid lipid nanoparticles (SLNs) as promising drug delivery systems. SLNs have garnered significant attention due to their unique properties, including biocompatibility, controlled drug release, and improved stability. The abstract explores the key aspects of SLN formulation, emphasizing the influence of lipid composition, surfactants, and production methods on particle size, drug loading, and release kinetics. The impact of these parameters on the pharmacokinetics and therapeutic efficacy of SLN-incorporated drugs is discussed. Furthermore, the review delves into the various methods employed for characterizing SLNs, such as dynamic light scattering, transmission electron microscopy, and X-ray diffraction, highlighting their roles in ensuring product quality. The abstract also touches upon recent advancements in SLN research, including surface modification strategies and their implications for targeted drug delivery.In conclusion, this review consolidates current knowledge on SLNs, offering valuable insights into their formulation, characterization, and potential applications in pharmaceutical research. The synthesis of relevant literature provides a foundation for researchers and practitioners to navigate the evolving landscape of SLN-based drug delivery systems.

Nanoformulated meloxicam and rifampin: inhibiting quorum sensing and biofilm formation in Pseudomonas aeruginosa.

Background: We aimed to investigate the simultaneous effects of meloxicam and rifampin nanoformulations with solid lipid nanoparticle (SLN) and nanostructured lipid carrier (NLC) substrates on inhibiting the quorum-sensing system of Pseudomonas aeruginosa and preventing biofilm formation by this bacterium. Methods: Antimicrobial activity of rifampin and meloxicam encapsulated with SLNs and NLCs against P. aeruginosa PAO1 was assessed by disk diffusion, minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC). Results: The SLN formulation was associated with lower doses for the MIC and minimum bactericidal concentration in comparison to NLC. Moreover, our results demonstrated that both nanoformulations were able to produce 100% inhibition of the biofilm formation of P. aeruginosa PAO1. Conclusion: All these findings suggest that meloxicam and rifampin encapsulated with SLNs could be the most effective formulation against P. aeruginosa.

Development of Curcumin and Turmerone Loaded Solid Lipid Nanoparticle for Topical Delivery: Optimization, Characterization and Skin Irritation Evaluation with 3D Tissue Model.

Curcuma longa L., commonly known as turmeric, is renowned for its therapeutic benefits attributed to bioactive compounds, namely curcumin (Cur) and aromatic turmerone (Tur), present in its rhizome. These compounds exhibit diverse therapeutic properties, including anti-inflammatory, antioxidant, and anti-tumor effects. However, the topical application of these compounds has a significant potential for inducing skin irritation. This study focuses on formulating solid lipid nanoparticle (SLN) carriers encapsulating both Cur and Tur for reduced irritation and enhanced stability. SLN formulations were prepared by a method using homogenization followed by ultrasonication procedures and optimized by applying response surface methodology (RSM). The optimized SLN formulation demonstrated entrapment efficiencies, with 77.21 ± 4.28% for Cur and 75.12 ± 2.51% for Tur. A size distribution of 292.11 ± 9.43 nm was obtained, which was confirmed to be a spherical and uniform shape via environmental scanning electron microscopy (ESEM) images. The in vitro release study indicated cumulative releases of 71.32 ± 3.73% for Cur and 67.23 ± 1.64% for Tur after 24 hours under sink conditions. Physical stability tests confirmed the stability of formulation, allowing storage at 4°C for a minimum of 60 days. Notably, in vitro skin irritation studies, utilizing the reconstructed human epidermal model (EPI-200-SIT), revealed a significant reduction in irritation with the SLN containing Cur and Tur compared to nonencapsulated Cur and Tur. These findings collectively endorse the optimized SLN formulation as a favorable delivery system for Cur and Tur in diverse topical uses, offering enhanced stability, controlled release and reduced irritation.

Formulation and characterization of solid lipid nanoparticles containing Camptotheca acuminata extract for the treatment of pancreatic cancer

To this day, pancreatic cancer remains not only one of the deadliest but also one of the most challenging types of the disease to successfully treat. Innovative therapy approaches are necessary if they are to be utilised in order to improve patient outcomes. The formulation and characterization of solid lipid nanoparticles (SLNs), which are intended for the targeted therapy of pancreatic cancer, are the primary objectives of this research. The solid lipid nanoparticles include an extract from Camptotheca acuminata, which has the possible ability to act as a natural anticancer drug. The goal of this research project is to enhance the therapeutic efficacy of an extract derived from Camptotheca acuminata by concentrating on the development of SLNs as a technique for the administration of drugs. SLNs have improved drug solubility, a longer period in circulation, and higher cellular absorption.

In-vitro and In-silico Examinations on Baicalein-loaded Solid Lipid Nanoparticles for Neurodegeneration

Background:: In the current scenario, most of the population affected by neurogenera-tive disorders like Alzheimer's, Parkinson's, Huntington's, etc., exist among the 10% population 65 years of age group. Neurodegenerative diseases are characterised as chronic and progressive disorders that occur due to the degeneration of neurons. Baicalein is a flavonoid glycoside derived from the roots of Scutellaria baicalensis. Earlier research suggested that it could be used to treat neurodegenerative illnesses. Baicalein, which was selected for the current study, was designed in-to a solid lipid nanoparticle (SLN) formulation. The SLNs have low permeability across BBB and are delivered by the non-invasive route, i.e., through nasal delivery. The In-silico docking studies were performed to examine and compare the binding affinity of Baicalein to already established drugs on the two most viable targets of Alzheimer's disease, i.e., Beta- secretase and Acetylcho-linesterase. Objective:: The current work is to formulate and evaluate the Baicalein-loaded SLN for neuro-degenerative disorders via a non-invasive route. Methods:: Baicalein loaded SLN was developed by solvent emulsification diffusion method, and formulation is characterised by using different parameters such as particle size analysis, zeta po-tential, scanning electron microscope, transverse electron microscope, X-ray diffraction, Differen-tial scanning calorimetric, Fourier transforms -infrared radiations, drug entrapment, in-vitro drug release and in-silico docking studies. Results:: The particle size of Baicalein-loaded SLN was 755.2 ± 0.48 nm, the Polydispersity index was 0.06, and the zeta potential was -32.5 ± 0.36 mV. The drug entrapment and loading efficien-cy of the optimised formulation were found to be 94% ± 0.653 and 18.2% ± 0.553, respectively. Optimised formulation shows 84.6% ± 0.3% of drug release within 30 minutes, which demon-strates the sustained release of the drug. Conclusion:: Baicalein-loaded SLN is formulated and evaluated for the treatment of neurodegen-erative disorders. SLN is an approach to overcome the challenge of bypassing the BBB by admin-istering the drug via an intranasal route. Hence, when analysed together with the results of Bai-calein-loaded SLN and in-silico studies, it was correlated that Baicalein proved to have a targeted moiety for neurodegeneration.

Formulation of Solid Lipid Nanoparticles Loaded with Rosiglitazone and Probiotic: Optimization and In-vitro Characterization.

In the present study, solid lipid nanoparticles loaded with Rosiglitazone and probiotics were prepared via solvent emulsification diffusion. As a lipid and surfactant, Gleceryl monostearate and Pluronic -68 were used in the formulation process. During characterization, it was determined that ingredient quantity variations significantly impacted Rosiglitazone loading capacity, particle size, polydispersity index, etc. In an optimized formulation of RSG-PB loaded SLNs, spherical particles with a mean particle size of 147.66±1.52 nm, PDI of 0.42±0.02, and loading capacity of 45.36±0.20 were identified. Moreover, the developed SLNs had the potential to discharge the drug for up to 24 hours, as predicted by Higuchi's pharmacokinetic model. The SLNs were stable at 25⁰C/60%RH for up to 60 days. There was little to no change in particle size, PDI, or loading capacity. In addition, the number of probiotic bacteria was determined using the standard plate count procedure. Further, the antioxidant effect of the prepared formulation is evaluated using the DPPH assay method. This study concludes that the method used to fabricate RSG-probiotic-loaded SLNs is straightforward and yields favorable results regarding various parameters, including sustained release property, particle size, PDI, and percent drug loading stability. Furthermore, DPPH radical scavenging activity shows the high antioxidant potential of RSG-PB SLNs when compared to RSG and probiotics alone.

Natural-Origin Betaine Surfactants as Promising Components for the Stabilization of Lipid Carriers.

In the present work, we demonstrate studies involving the influence of the formulation composition on the physicochemical properties of nanocarriers: solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs). Novel lipid-origin platforms were prepared using two "green" betaine-based surfactants, cocamidopropyl betaine (ROKAmina K30) and coco betaine (ROKAmina K30B), in combination with three different solid lipids, cetyl palmitate (CRODAMOL CP), trimyristin (Dynasan 114), and tristearin (Dynasan 118). Extensive optimization studies included the selection of the most appropriate lipid and surfactant concentration for effective SLN and NLC stabilization. The control parameters involving the hydrodynamic diameters of the obtained nanocarriers along with the size distribution (polydispersity index) were determined by dynamic light scattering (DLS), while shape and morphology were evaluated by atomic force microscopy (AFM) and transmission electron microscopy (TEM). Electrophoretic light scattering (ELS) and turbidimetric method (backscattering profiles) were used to assess colloidal stability. The studied results revealed that both betaine-stabilized SLN and NLC formulations containing CRODAMOL CP as lipid matrix are the most monodisperse and colloidally stable regardless of the other components and their concentrations used, indicating them as the most promising candidates for drug delivery nanosystems with a diverse range of potential uses.

Characterization and stability of solid lipid nanoparticles produced from different fully hydrogenated oils

The use of lipids from conventional oils and fats to produce solid lipid nanoparticles (SLN) attracting interest from the food industry, since due their varying compositions directly affects crystallization behavior, stability, and particle sizes (PS) of SLN. Thus, this study aimed evaluate the potential of fully hydrogenated oils (hardfats) with different hydrocarbon chain lengths to produce SLN using different emulsifiers. For that, fully hydrogenated palm kern (FHPkO), palm (FHPO), soybean (FHSO), microalgae (FHMO) and crambe (FHCO) oils were used. Span 60 (S60), soybean lecithin (SL), and whey protein isolate (WPI) were used as emulsifiers. The physicochemical characteristics and crystallization properties of SLN were evaluated during 60 days. Results indicates that the crystallization properties were more influenced by the hardfat used. SLN formulated with FHPkO was more unstable than the others, and hardfats FHPO, FHSO, FHMO, and FHCO exhibited the appropriate characteristics for use to produce SLN. Concerning emulsifiers, S60- based SLN showed high instability, despite the hardfat used. SL-based and WPI-based SLN formulations, showed a great stability, with crystallinity properties suitable for food incorporation.

Formulation and evaluation of solid lipid nanoparticles of naringin to enhance its bioavailability

The objective of the present work was to formulate solid lipid nanoparticles loaded with naringin for improving the bioavailability of naringin. The SLNs loaded with naringin were prepared by using different ratio of palmitic and stearic acid as the lipids and Tween 80 as the surfactant. The method nanoprecipitation was used for preparation of the SLNs. The surfactant (Tween 80) helps in steric stabilization of the SLNs. The size range of SLNs obtained on sonicating for 7 was found to be 429 ± 76 nm when stearic acid was used and 365 ± 28 nm when palmitic acid was used for the preparation of SLNs. The zeta potential of all the SLNs ranged from -16 to -27 mV suggesting a stable formulation. The percentage of drug incorporated during nanoparticle preparation was determined by centrifuging the drug loaded nanoparticles at 15,000 rpm for 15 min and separating the supernatant. The highest encapsulation of naringin (71.7 ± 8.6 %) was obtained when the concentration of palmitic acid was 0.14 mmol. The in vitro release of naringin from the SLNs was measured by dialysis method using simulated gastric fluid as the dissolution medium. In vitro release kinetics studies for naringin loaded SLNs exhibited a sustained release pattern. Sustained release was observed over a period of 3 days. The stability of NSLN-7 was studied by storing at 4 ± 1 °C for 30 days. The particle size remained stable at the end of the study with drug entrapment of 71.5 %. This suggests that the SLNs prepared are stable on storage.

Preparation and characterization of solid lipid nanoparticles encapsulated noscapine and evaluation of its protective effects against imiquimod-induced psoriasis-like skin lesions

Psoriasis is a chronic inflammatory skin disease characterized by thickening the epidermis with erythema, scaling, and proliferation. Noscapine (NOS) has several anti-inflammatory, anti-angiogenic, and anti-fibrotic effects, but its low solubility and large size results in its lower efficacy in the clinic. In this regard, solid lipid nanoparticles (SLN) encapsulated NOS (SLN-NOS) were fabricated using the well-known response surface method based on the central composite design and modified high-shear homogenization and ultrasound method. As a result, Precirol® was selected as the best lipid base for the SLN formulation based on Hildebrand-Hansen solubility parameters, in which SLN-NOS 1 % had the best zeta potential (−35.74 ± 2.59 mV), average particle size (245.66 ± 17 nm), polydispersity index (PDI, 0.226 ± 0.09), high entrapment efficiency (89.77 %), and ICH-based stability results. After 72 h, the SLN-NOS 1 % released 83.23 % and 58.49 % of the NOS at pH 5.8 and 7.4, respectively. Moreover, Franz diffusion cell’s results indicated that the skin levels of NOS for SLN and cream formulations were 46.88 % and 13.5 % of the total amount, respectively. Our pharmacological assessments revealed that treatment with SLN-NOS 1 % significantly attenuated clinical parameters, namely ear thickness, length, and psoriasis area and severity index, compared to the IMQ group. Interestingly, SLN-NOS 1 % reduced the levels of interleukin (IL)-17, tumor necrosis factor-α, and transforming growth factor-β, while elevating IL-10, compared to the IMQ group. Histology studies also showed that topical application of SLN-NOS 1 % significantly decreased parakeratosis, hyperkeratosis, acanthosis, and inflammation compared to the IMQ group. Taken together, SLN-NOS 1 % showed a high potential to attenuate skin inflammation.

Design Characterization and Stability studies of Mesalamine Loaded Solid Lipid Nanoparticles

Background: Solid lipid nanoparticles are a colloidal carrier system for topical, oral, and parenteral administration that are utilized to increase the bioavailability of mostly lipophilic medications. Mesalamine is an anti-inflammatory drug that works in inflammatory bowel disease and is structurally similar to salicylates. In the current study, glycerylmonostearate was used as a lipid, Tween 80 as a surfactant, and cremophor as a solubilizing agent to enhance the formulation, evaluation, and stability studies of mesalamine-loaded solid lipid nanoparticles. Results: Particle size, entrapment efficiency, scanning electron microscopy, and differential scanning calorimetry were used to characterize the formulations. The drug concentration in the MES-SLNs F-7 was found to be 334mg in a 100ml solution of SLNs, and the size of the MES-SLNs F-7 was 82.1±5.37nm. the zeta potential was -13.9mV, the polydispersity index was 0.35 0.15, and the formulated MES-SLNs showed burst release. The physical stability of the formulated MES-SLNs was determined by measuring the size of the MES-SLNs, and colour stored at four different temperatures (-20C, 40C, room temperature, and 400C) for three months. High Performance Liquid Chromatographic analysis was used to determine the MES-SLNs' chemical stability. At -20°C and 40°C, it was discovered that MES-SLNs were stable. Conclusion: The chemical stability of MES-SLNs was determined by HPLC analysis. It was found that MES-SLNs were stable at -20C and 40ºC.

Solid lipid nanoparticle formulation and antihyperglycemic activity test of sea cucumber (Stichopus hermanii)

This study aims to develop a formulation with the active ingredient Stichopus hermanii for antidiabetic treatment or function to lower blood glucose levels. The formulation approach taken is to design a formula in the form of solid lipid nanoparticles (SLN), where this system is expected to optimize absorption and improve the performance of the active substance. The SLN characterization includes particle size measurement, zeta potential, polydispersity index analysis, and morphology analysis using TEM. The antihyperglycemic activity test will be tested in vivo using male white rats using the glucose tolerance test method and induced by streptozotocin. The results of the TEM analysis showed that the sea cucumber spherical in shape. The particle size of the formula was found to be 0.25 nm. The polydispersion index (PDI) of the formulation was 67.5%, 2%, and 0.5%, respectively. In the same test, male rats were given treatment according to the group division, namely 50% glucose at a dose of 3 g/kg bw 30 minutes later and the blood sugar levels were measured at 30, 60, 90, and 120 minutes using a glucometer. In a follow-up test, the administration of test samples (days -3, 6, 9, 12, and 15) of CMC Na, metformin, and 25 mg/kg body weight of the test group showed that blood sugar level decreased with the highest decrease in positive control group. In conclusion, the results showed that sea cucumbers could be developed as a functional food product to help battle the onset of diabetes and diabetic complications.

Formulation and Characterization of Solid Lipid Nanoparticles Loaded with Troxerutin

Troxerutin (TXR), a naturally derived compound with diverse therapeutic potential, faces limitations in clinical efficacy due to poor bioavailability and rapid plasma clearance. This study focuses on troxerutin-loaded solid lipid nanoparticles (TXR-SLNs) and their physicochemical properties, intending to enhance drug release. TXR-SLNs were prepared via high-shear homogenization followed by ultrasonication, yielding optimized nanoparticles with an average size of 140.5 ± 1.02 nm, a uniform distribution (polydispersity index: 0.218 ± 0.01), and a stable emulsion (zeta potential: 28 ± 8.71 mV). The formulation exhibited 83.62% entrapment efficiency, indicating improved drug-loading capacity and extended drug release. Spectroscopic and thermodynamic analyses confirmed component compatibility. Despite a decline in entrapment efficiency induced by temperature after one month of storage at 23 °C, the formulation may retain acceptable stability. This study provides insight into SLNs as effective carriers for enhancing troxerutin’s release profile, motivating further in vivo investigations to optimize therapeutic interventions.

Development of Solid Lipid Nanoparticles for Controlled Amiodarone Delivery.

In various drug delivery systems, solid lipid nanoparticles are dominantly lipid-based nanocarriers. Amiodarone hydrochloride is an antiarrhythmic agent used to treat severe rhythm disturbances. It has variable and hard-to-predict absorption in the gastrointestinal tract because of its low solubility and high permeability. The aims of this study were to improve its solubility by encapsulating amiodarone into solid lipid nanoparticles using two excipients-Compritol® 888 ATO (pellets) (C888) as a lipid matrix and Transcutol® (T) as a surfactant. Six types of amiodarone-loaded solid lipid nanoparticles (AMD-SLNs) were obtained using a hot homogenization technique followed by ultrasonication with varying sonication parameters. AMD-SLNs were characterized by their size distribution, polydispersity index, zeta potential, entrapment efficiency, and drug loading. Based on the initial evaluation of the entrapment efficiency, only three solid lipid nanoparticle formulations (P1, P3, and P5) were further tested. They were evaluated through scanning electron microscopy, Fourier-transform infrared spectrometry, near-infrared spectrometry, thermogravimetry, differential scanning calorimetry, and in vitro dissolution tests. The P5 formulation showed optimum pharmaco-technical properties, and it had the greatest potential to be used in oral pharmaceutical products for the controlled delivery of amiodarone.

Solid Lipid Nanoparticles (SLN): Formulation and Fabrication

Solid lipid nanoparticles (SLN) have emerged as a novel drug delivery system and have been utilized for delivering various kinds of drugs since the 1990s. These particles may consist of multiple solid lipids, including glycerides, waxes, and fatty acids, and can be stabilized by a wide range of surfactants. SLN have garnered significant attention from researchers due to its innovative and versatile nature. Moreover, such delivery system has numerous advantages over traditional colloidal carriers, such as liposomes, polymeric nanoparticles, and emulsions. Several research groups have been developing SLN formulations and fabrication techniques based on their intended purpose, and this research number is still increasing globally. Given the vast potential for the development of SLN in the future, coupled with the wide variety of materials and techniques to be considered during the manufacturing process, this paper provides an extensive overview of the general introduction of SLN, their benefits and drawbacks, and the numerous excipients which can be associated with the SLN formulation. Various aspects related to the models of drug incorporation and fabrication methods are also systematically discussed in this review. In addition, an analysis of the factors that impact the stability of the SLN will also be documented to provide further insight for future advancements in SLN research.